Rituximab, Gemcitabine and Oxaliplatin (R-GEMOX) for Refractory/Relapsed B-cell Lymphoma
Status:
Completed
Trial end date:
2012-11-01
Target enrollment:
Participant gender:
Summary
The Purpose of this study is to evaluate the efficacy and the safety of R-GEMOX in
refractory/relapsed patients with CD20-positive large B-cell lymphoma who are not eligible
for autologous transplantation.
Phase:
Phase 2
Details
Lead Sponsor:
Lymphoma Study Association
Collaborators:
Eli Lilly and Company Hoffmann-La Roche Sanofi-Synthelabo